ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative211.4 M258.4 M249.5 M221.5 M233 M962.4 MRicerca e sviluppo27.8 M26.7 M22 M24.9 M21.8 M95.4 MReddito operativo114.2 M46.9 M45.4 M72.6 M-1.29 B-1.12 BProventi non operativi, Totale600 K400 K-2.6 M-9.6 M-1.4 M-13.2 MOneri finanziari, al netto degli interessi capitalizzati8 M2.3 M2.3 M2.4 M2.5 M9.5 MProventi non operativi, esclusi gli oneri finanziari-8 M-2.3 M-2.3 M-2.4 M-2.5 M-9.5 MEntrate/uscite straordinarie600 K400 K-2.6 M-9.6 M-1.4 M-13.2 MUtile al lordo delle imposte70.1 M8.3 M3.2 M22.4 M-1.33 B-1.3 BQuota di utile-300 K-100 K-400 K-200 K-33.6 M-34.3 MImposte111.6 M8.2 M3.7 M9.7 M82.8 M104.4 MInteressi di minoranza——————Altri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate-41.5 M100 K-500 K12.7 M-1.41 B-1.4 BAttività cessate-2.9 M-6.5 M-7.9 M-5.2 M-3.5 M-23.1 MUtile netto-44.4 M-6.4 M-8.4 M7.5 M-1.42 B-1.43 BRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari-44.4 M-6.4 M-8.4 M7.5 M-1.42 B-1.43 BUtile base per azione (EPS base)-0.32-0.05-0.060.05-10.23-10.29Utile diluito per azione (EPS diluito)-0.32-0.05-0.060.05-10.23-10.29Numero medio di azioni ordinarie in circolazione137.4 M137.7 M138.2 M138.5 M138.5 M552.9 MAzioni diluite in circolazione137.4 M137.7 M138.2 M138.9 M138.5 M553.3 MEBITDA194.5 M126.8 M131.7 M158 M-1.2 B-784.7 MEBIT114.2 M46.9 M45.4 M72.6 M-1.29 B-1.12 BCosto del fatturato752.4 M651.6 M693.4 M666.2 M747.4 M2.76 BAltri costi del venduto——————Ammortamento e svalutazione (liquidità)80.3 M79.9 M86.3 M85.4 M85.9 M337.5 M
Perrigo Company plc
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
Perrigo engages in the acquisition, manufacture, and sale of consumer healthcare products, generic prescription drugs, and active pharmaceutical ingredients, primarily in the United States, from its base in Ireland. On 21 December 2018, Perrigo suffered its biggest one-day share price fall in its history after the Irish Revenue Commissioners issued a tax claim against Perrigo that equated to half of its market value.